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Abstract
OBJECTIVE: To investigate the effects of Qingx-
inkaiqiao (QK) compound in a rat model of Alzheim-
er's disease induced with β-amyloid (Aβ) 1-40.
METHODS: Fifty-six three months, male,
Sprague-Dawley rats were randomly divided into
seven groups: blank control group, surgery group,
model group, low-dose QK group, middle-dose QK
group, high-dose QK group, and Aricept (donepezil
hydrochloride) group, with eight rats in each
group. Apart from the control and surgery groups,
an Alzheimer's disease model was established in all
groups by bilateral hippocampal injection of Aβ
1-40. The surgery group received an injection of
the same volume of physiological saline. Two days
after model establishment, rats from the drug
groups were administered the corresponding
drugs; the control group and model group were ad-
ministered an equal volume of physiological saline
for 14 days. After treatment, real-time quantitative
polymerase chain reaction, immunohistochemistry,
and western blot assay were employed to confirm
mRNA and protein expressions of Bcl-2, Bax, cas-
pase-3, and Aβ, respectively.
RESULTS: Compared with the model group, Bcl-2
expression increased and Bax, caspase-3, and Aβ
expression decreased in each drug treatment
group (P < 0.05, P < 0.01). The expressions of mid-
dle-dose QK group were more significant than the
high- and low-dose QK groups (P < 0.01, P > 0.05).
CONCLUSION: QK treatment resulted in significant-
ly up-regulated Bcl-2 expression, down-regulated
Bax, caspase-3, and Aβ expression, and reduced
numbers of apoptotic cells in the cortex.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Alzheimer's disease (AD) is a common neurological de-
generative disease in the elderly, characterized by a pro-
gressive decline in memory and cognitive function, and
often accompanied by personality change. The inci-
dence of AD increases with age. The symptoms and
eventual cognitive decline have placed a large burden
on family members and society. Because of the in-
creased age of our society, there is a great need for in-
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creased attention to this devastating disease. There re-
mains no effective modern treatment for Alzheimer's
disease, but Traditional Chinese Medicine provides a
unique therapeutic perspective for dementia.
Qingxinkaiqiao (QK) compound from the "Fumanji-
an" is a Chinese medicine recipe documented in the
medical book Jingyue Quanshu,1 written by Zhang
Jing-yue during the Ming Dynasty. It has been used in
clinical practice for many years. It can significantly im-
prove cognitive dysfunction, as well as behavioral and
psychological symptoms in patients.2-4 Previous results
from our group showed that QK improves learning
and memory in AD rats and decreases apoptosis in the
hippocampal region.5 The present study aimed to inves-
tigate the effects of QK on cortical expression of B-cell
lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax),
cysteinyl aspartate specific proteinase-3 (Caspase-3),
and β-amyloid precursor protein (Aβ) in a rat model
of AD induced by Aβ1-40.
MATERIALS ANDMETHODS
Experimental animals
Fifty-six male, specific pathogen-free, 3-month-old
Sprague-Dawley (SD) rats weighing (250 ± 20) g were
purchased from the Beijing Vital River Laboratory Ani-
mal Technology Co., Ltd. [Certification No. SCXK
(Beijing) 2012-0001]. Rats were bred at the Wenzhou
Medical University Laboratory Animal Center (clean
experimental and standard animal feeding conditions).
The rats were housed in a room with a 12-h light/dark
cycle. The animals were subjected to experimentation
after acclimatization for 1 week at 23-25 ℃ and rela-
tive humidity of 55% ± 5%, with free access to stan-
dard food and water. All experimental conditions fol-
lowed ethical requirements related to experimental ani-
mals.
Drugs and reagents
The following herbs were purchased from the Dispen-
sary of Traditional Chinese Medicine (Second Affiliat-
ed Hospital of Wenzhou Medical University and veri-
fied by the Department of Chinese Materia Medica of
Wenzhou Medical University): Dihuang (Radix Rehm-
anniae) 6 g, Baishao (Radix Paeoniae Alba) 6 g,
Shichangpu (Rhizoma Acori Tatarinowii) 6 g, Maidong
(Radix Ophiopogonis Japonici) 6 g, Mudanpi (Cortex
Moutan Radicis) 6 g, Fushen (Poria Cum Radix Pini) 6
g, Kushen (Radix Sophorae Flavescentis) 6 g, Shihu (Her-
ba Dendrobii Nobilis) 6 g, Chenpi (Pericarpium Citri Re-
ticulatae) 4 g, and Zhimu (Rhizoma Anemarrhenae) 5 g.
The raw herbs were decocted with appropriate
amounts of water, extracted two times, filtered and con-
centrated to drug stocks of 1 g/mL (crude drug), and
stored at 4 ℃ . Donepezil (Eisai Pharmaceutical, Su-
zhou, China; batch number: 100223A) was made into
a water suspension of the designed concentration prior
to administration.
Reagents (sources) used in the study were as follows:
Aβ1-40 and DMSO were purchased from Sigma (St.
Louis, MO, USA); DAB chromogenic reagent kits
were purchased from Zymed (San Diego, CA, USA);
Hematin dye solution was purchased from Fir Biologi-
cal (Beijing, China); Trizol Reagent was purchased
from ShengGong Biological Engineering (Shanghai,
China); Reverse transcriptase, fluorescence quantitative
Ploymerase Chain Reaction (PCR) and SYBR green I
were purchased from Bioneer (Daejeon, Korea). The
quantitative PCR primers were purchased from Dalian
Treasure Biological Engineering (Dalian, China); rab-
bit anti-rat BAX actin antibody, rabbit anti-rat Bcl-2
actin antibody and horseradish peroxidase (HRP)-con-
jugated goat anti-rabbit secondary antibody were pur-
chased from Cell Signal Technology (Beverly, MA,
USA); rabbit anti-rat caspase-3 antibody and rabbit an-
ti-rat Aβactin antibody were purchased from Bioworld
Technology (St. Louis, MO, USA); chloral hydrate was
purchased from Sinopharm Chemical Reagent (Shang-
hai, China); BCA protein assay kit and enhanced che-
miluminescence kit were purchased from Pierce (Rock-
ford, IL, USA).
Establishment of animal model and grouping
Aβ1-40 was incubated according to the manufacturer's
instructions to allow the change in an assembly state of
the peptide with ensuing toxicity. Fifty-six rats were
used in the experiment.6 Except for the randomly cho-
sen 8 rats that served as the normal controls, the re-
maining 48 rats were sedated with 10% chloral hydrate
(3-4 mL/kg) by intraperitoneal injection. The hair on
the skull was shaved and the skin was disinfected with
75% alcohol. The skin on the skull was then incised
and the periosteum was removed. Referring to the Paxi-
nos and Watson Rat Brain Atlas,7 the bregma served as
the 0 point. Then, 3 mm ventral from bregma, a crani-
al drill was employed to drill a hole through the skull
1.5 mm to the left and right of the midline. A needle
was inserted 3 mm deep and a microsyringe was used
to infuse 2 μL double-distilled H2O bilaterally into the
hippocampus of the sham-surgery group. The remain-
ing groups were injected with 2 μL Aβ1-40 at a con-
centration of 2.5 μg/μL (equivalent to 5 μg Aβ) and a
speed of 0.5 μL/min. The needle was then held in
place for 10 minutes after infusion to prevent leakage.
Once the needle was removed, the scalp was sutured
and iodine was used to disinfect the incision. Except
for the normal control group (0 + NS) and the
sham-surgery group (NS + NS), the remaining 40 suc-
cessfully established model rats were randomly divided
into five groups according to a random number se-
quence generated by a computer, with eight rats in
each group: model control group (Aβ + NS), positive
control group (Aβ + Aricept) treated with Aricept
[1.67 mg·kg－1·d－1], and three QK-treated groups (Aβ
+ L-FJ/Aβ + M-FJ/Aβ + H-FJ) treated respectively
with QK at various dosages according to the equivalent
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adult human clinical dose (low-dose QK: 4.75 mg·kg－1·
d－ 1; middle-dose QK: 9.5 mg·kg－ 1·d－ 1; high-dose
QK: 19 mg·kg－1·d－1. Starting the following day, the
rats were intragastrically administered the respective
QK dose place for 14 days at a volume of 10 mg·kg－1·
d－ 1 (starting at 10 o'clock in the morning every day).
The control and model groups were given equivalent
volumes of normal saline solution.
Cortex sample handling
At the end of the experiment, the rats were anaesthe-
tized with 10% chloral hydrate (3-4 mL/kg) via intra-
peritoneal injection. The rats were then connected to
the infusion apparatus, and the chest was opened along
both sides of the sternum avoiding large blood vessels
to expose the heart. A needle was inserted into the tip
of the heart and into the aorta. The needle was then
fixed with a vascular clamp and the right atrial append-
age was incised. Cold saline (250 mL) was infused un-
til the liver was clear, which was followed by 250 mL
cold (4 ℃) paraformaldehyde. The brains were quickly
removed and further fixed in 4% paraformaldehyde.
The cortex was rapidly separated from the brain and
stored at－80℃.
Quantification of mRNA expression of Bcl-2, Bax,
caspase-3, and Aβ in the cortex using real-time
quantitative PCR
Measurement of concentration and integrity detection
of total RNA extraction. Total RNA was extracted ac-
cording to Trizol kit instructions. RNA integrity was
tested by separating the RNA by 1.5% agarose gel elec-
trophoresis. The RNA solution was diluted and zeroed
with diethypyrocarbonate water (DEPC water). The
OD values (A260/A280) at 260 nm and 280 nm were
obtained by ultraviolet spectrophotometer to determine
RNA purity and to calculate the RNA concentration.
Synthesis of cDNA. A mixture of 1.0 μL (1.0 μg/μL)
template total RNA, 2.0 μL (T18, 10 pmol/μL) and
2.0 μL (10 mmol/L) dNTP mix was placed into a cen-
trifuge tube (0.5 mL) and water was added to a total of
15.0 μL. After mixing, the RNA was denatured for 10
min at 25 ℃ . The sample was centrifuged to collect
the solution at the bottom of the centrifuge tube, and
then 4.0 μL 5× reaction buffer, 1.0 μL RNase inhibi-
tor, and 1.0 μL M-MLV RT were added to the sample,
water was added to a total of 25.0 μL. The reaction
was extended at 42 ℃ for 60 min, maintained at 85 ℃
for 5 min, and then terminated. The synthesized cD-
NA was stored at－20℃.
Design of PCR primer. Primers for Bcl-2 mRNA, Bax
mRNA, caspase-3 mRNA, and Aβ mRNA were de-
signed according to the standard principle of real-time
PCR primer designation (Shanghai Rui Jingsheng Bio-
logical Engineering Co., Ltd., Shanghai, China).
Fluorescence real-time quantitative PCR detection.
The reaction mixture was as follows (50 μL total): 25 μL
2× PCR buffer, 0.6 μL × 2 primers (25 pmol/μL), 0.3 μL
SYBR green I (20×), 1 μL cDNA template, and 22.5 μL
DEPC H2O. The PCR amplification reaction condi-
tions were as follows: 94℃ for 4 min; 94℃ for 20 sec-
onds, 60 ℃ for 30 seconds, and 72 ℃ for 30 seconds
for 35 cycles, following by 72 ℃ elongation. Dissolu-
tion curve analyses were performed on the amplified
PCR products. Sequence Detection Software 2.2 was
used to analyze the data and calculate the Ct value,
which was the value for each sample to reach the
threshold value during PCR amplification. The relative
expression quantities of each sample (Bcl-2/β-actin,
Bax/β-actin, caspase-3/β-actin, and Aβ/β-actin) were
obtained following β-actin correction (Table 1).
Western blot assay
Following extraction of tissue protein, the protein con-
centration was determined using the BCA protein as-
say kit according to kit instructions. The OD562 value
and the protein concentration standard curve were
used to calculate the total sample protein concentra-
tion. Tissue extracts were analyzed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis. Equal
amounts of protein were subjected to electrophoresis
on 10% SDS-PAGE gels and then the proteins were
Primers
Bcl-2
Bax
Caspase-3
Aβ
β-actin
Sequence (5'-3')
Upstream
Downstream
Upstream
Downstream
Upstream
Downstream
Upstream
Downstream
Upstream
Downstream
Amplified fragment length
GTGAACTGGGGGAGGATTGT
GCATCCCAGCCTCCGTTA
CCCGAGAGGTCTTCTTCCG
GAAGTCCAGTGTCCAGCCCA
CGAAACTCTTCATCATTCAGGC
AGTAAGCATACAGGAAGTCGGC
CTGGAGGTGCCCACTGATG
GGGTCTGACTCCCATTTTCC
CCCATCTATGAGGGTTACGC
TTTAATGTCACGCACGATTTC
bp
167
-
167
-
129
-
150
-
150
-
Annealing temperature (℃)
51
-
50
-
54
-
55
-
51
-
Table 1 Ploymerase chain reaction primers
656
Hu HY et al. / Experimental Study
JTCM |www. journaltcm. com October 15, 2016 |Volume 36 | Issue 5 |
transferred to polyvinylidene difluoride (PVDF) mem-
branes using an electrophoretic transfer system. The
PDVF membranes were then blocked for 1 h at room
temperature and incubated with primary antibodies
(Bax, Bcl-2, and caspase-3 were diluted 1∶500, and Aβ
was diluted 1∶100 in TBS) overnight at 4 ℃ . After
three washes with TBST for 5 min each, the mem-
branes were incubated with horseradish peroxidase-con-
jugated goat anti-rabbit secondary antibody (1∶1000)
at room temperature for 2 h. Finally, after washing the
membranes three times with TBS for 5 min each, im-
mune-labeled bands were identified by using a chemilu-
minescence-based detection kit (Pierce). The OD val-
ues for Bax, Bcl-2, caspase-3, Aβ, and β-actin were ob-
tained using the Quantity One Gel Analysis System
(Bio-Rad, Hercules, USA)as follows: target-protein op-
tical density ratio = optical density value of the target
protein. To reduce experimental error, the western blot
assay was performed three times for each rat.
Immunohistochemistry and quantitative analysis
The fixed brain tissues were dehydrated through an al-
cohol gradient, followed by xylene. The tissues were
then embedded in paraffin and sectioned on a cryostat
at a thickness of 5 μm. Sections were dewaxed and sub-
jected to 3% H2O2 for 10 min, followed by several
washes in distilled water. Then sections to heat-mediat-
ed antigen retrieval with 0.01 M citric acid buffer (pH
6.0). Following several washes in phosphate-buffered
saline (PBS), sections were bolcked with 10% goat se-
rum (30 min), and then incubated with rabbit anti-rat
BAX antibody (1∶1000), Bcl-2 antibody (1∶1000),
Caspase-3 antibody (1∶1000) and Aβ antibody (1∶
1000) at 4 ℃ overnight. After incubation with the goat
secondary antibody, at room temperature for 2 h. After
detected with a DAB staining kit, the sections were
counterstained with hematoxylin. The MIAS Medical
System (Media Cybernetics, Rockville, MD, USA) was
used for image analysis. A total of six sections were se-
lected for each group, and five fields were analyzed on
each section (× 400 magnification). All positive cells
were selected within the view, and the computer soft-
ware IPP6.0 image analysis system (Media Cybernet-
ics) automatically calculated the cell density. The posi-
tive target area/total area of the field of view was calcu-
lated for quantitative expression.
TUNEL assay
To detect cells undergoing apoptosis, TUNEL was per-
formed according to the manufacturer's protocol sup-
plied within the TUNEL-pod kit (Roche, Basle, Swit-
zerland). The brain sections were first immersed in xy-
lene and dehydrated through serial alcohol dilutions
followed by a wash step in distilled water. After treat-
ing with 3% H2O2 for 10 min at room temperature,
the sections were incubated with proteinase K for
20 min at 37°C to enhance permeability. Then, the
sections were incubated for 60 min with TUNEL reac-
tion mixture and for 30 min with converter-POD at
37 ℃. After incubating for 10 min with DAB substrate
solution (Zymed, San Diego, CA, USA), the sections
were counterstained with hematoxylin, and then exam-
ined under a light microscope. Positive and negative
controls were included on slides from the same block.
Stained slides were randomly observed at a high-power
field (× 400 magnification), and pathological changes
near the injection site were photographed. The image
pictures were processed using America IPP6.0 software
(Media Cybernetics, Rockville, MD, USA) and the
apoptotic ratio was calculated according to the follow-
ing formula: apoptotic ratio = number of TUNEL-posi-
tive cells/ total number of cells.
HE staining
In brief, after the paraffin sections were dewaxed, hema-
toxylin staining was performed for 3 min, followed by
eosin staining for 3 s. The sections were then dehydrat-
ed with alcohol, followed by xylene, and then cover-
slipped. Cortical histopathological abnormalities were
investigated under a light microscope. Two different pa-
thologists quantified the number of cells in the cortical
region of each section in a blinded manner, and the av-
erage number was served as the final result.
Statistical analysis
All data were processed using SPSS 16.0 statistical soft-
ware (SPSS, Chicago, IL, USA). All data were ex-
pressed as mean ± standard deviation ( xˉ ± s). Least sig-
nificant difference and Dunnett test were performed
for group comparisons. P < 0.05 was the statistically
significant level.
RESULTS
Comparison of mRNA expression of Bcl-2, Bax,
caspase-3, and Aβ in the cortex
Results showed no significant difference in mRNA ex-
pression of Bcl-2, Bax, caspase-3, and Aβ between the
normal control and the sham-surgery groups (P >
0.05). Compared with the normal control group, Bcl-2
mRNA expression in the model control group signifi-
cantly decreased, whereas Bax, caspase-3, and Aβ
mRNA expressions significantly increased (P < 0.01).
Compared with the model control group, Bcl-2
mRNA expression in each treatment group significant-
ly increased, but Bax, caspase-3, and Aβ mRNA expres-
sions significantly decreased (P < 0.01). Bcl-2 mRNA
expression in the middle-dose QK group significantly
increased, but Bax, caspase-3, and Aβ mRNA expres-
sions significantly decreased compared with the
low-dose and high-dose group (P < 0.01). Compared
with the Aricept group, Bcl-2 mRNA expression in the
low-dose and high-dose groups were decreased, but no
significant differences in Bax mRNA expression were
found in the two groups (P > 0.05) (Figure 1).
657
JTCM |www. journaltcm. com October 15, 2016 |Volume 36 | Issue 5 |
Hu HY et al. / Experimental Study
Comparison of Bcl-2, Bax, caspase-3, and Aβ
protein expressions in the cortex of AD rats
To investigate changes in Bcl-2, Bax, caspase-3, and
Aβ protein expression in the cortex, we used western
blot analysis. Results are shown in Figure 2. There was
no significant different in Bcl-2, Bax, caspase-3, and
Aβ protein expressions between the normal control
group and the surgery control group (P > 0.05). Bax,
caspase-3, and Aβ protein expression significantly in-
creased in the model control group rats, and Bcl-2 pro-
tein significantly decreased, compared with the
sham-surgery group (P > 0.01). Compared with the
model control group, Bcl-2 mRNA expression in each
treatment group significantly increased, but Bax, cas-
pase-3, and Aβ mRNA expressions significantly de-
creased (P < 0.01). However, there were no differences
in Bcl-2, Bax, caspase-3, and Aβ protein expression be-
tween the middle-dose QK group and the Aricept
group (P > 0.05) (Figure 2).
Immunohistochemistry of Bcl-2, Bax, caspase-3, and
Aβ in the cortex
In the AD model group, there was a significant in-
crease in the number of cells expressing Bax, caspase-3,
and Aβ in the cortex, and a significant decrease in the
number of cells expressing Bcl-2 (P < 0.01; Figure 3)
compared with the other groups. Following treatment
with donepezil or QKF, these results were reversed.
The 9.5 mg·kg－ 1·d－ 1 QK dose produced the stron-
gest effect, which was compared with 4.75 and 19 mg·
kg－ 1·d－ .
TUNEL assay results
Microscopic inspection of the cortical sections from
normal control and sham-surgery rats revealed morpho-
logically normal neurons with no TUNEL reaction.
Compared with the control group, the number of
apoptotic cells significantly increased in the model
group (P < 0.01; Figure 4). After treatment with done-
pezil or QK, the number of TUNEL-positive cells sig-
nificantly decreased compared with the model group
(P < 0.01). The 9.5 mg·kg－1·d－1 QK dose produced
the strongest effect, which was comparable to 4.75 or
19 mg·kg－1·d－1.
HE staining
HE staining revealed no remarkable neuronal abnor-
malities in the cortex of rats in the control and
sham-surgery groups. The pyramidal cells were neatly
and tightly arranged, and no cell loss was found. Addi-
tionally, for these groups, the cells were round and in-
tact with clear, dark-blue nuclei (Figure 5). However,
obvious cortical histopathological damage was ob-
served in the model groups. The pyramidal layered
structure was disintegrated, and neuronal loss was
found. Neurons with pyknotic nuclei and with a
shrunken or irregular shape were also observed (Figure
5C). These abnormalities were attenuated by treat-
ment. The cells in the Aricept and QK groups exhibit-
ed better cell morphology and were more numerous
than in the model group, but were overall worse than
in the control and sham-surgery groups (Figure 5D,
5E).
DISCUSSION
AD is the most common type of dementia. The inci-
dence of AD increases with age, which is compounded
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by the fact that people are living longer these days.
There are many hypotheses for AD etiology, including
the Aβ waterfall hypothesis,8,9 immune and inflamma-
tory involvement hypothesis,10,11 the cholinergic defects
hypothesis,12,13 the tau protein hyperphosphorylation
hypothesis,14,15 the intracellular calcium homeostasis dis-
orders hypothesis,16,17 and the peroxidation hypothe-
sis.18 It has been suggested that the incidence of AD is
caused by multiple factors, and Aβ deposition in neu-
ronal cells of the brain is the initial event that occurs in
AD.19 Therefore, for the present study, the bilateral hip-
pocampi of rats were injected with Aβ1-40 fragments
to establish an experimental model of AD. This meth-
od has been shown to be stable and reliable and very ef-
fectively simulates the pathological and pathophysiolog-
ical characteristics of AD.20-22
Aβ is neurotoxic and induces apoptosis through a se-
ries of pathological and physiological mechanisms that
lead to AD,23 such as activation of glial cells, which ini-
tiates neuroinflammation,24 induction of the inflamma-
tory cascade,25 induction of oxidative stress mecha-
nisms,26,27 and excessive expression of NO and NO tox-
icity.28 Taken together, these results suggest that Aβ-in-
duced neuronal apoptosis is an important pathological
characteristic of AD. Caspase-3 is an effector of apopto-
sis and the final executor of apoptosis.29 The Bcl-2 fami-
ly is intricately involved in neuronal apoptosis; Bcl-2 is
an important endogenous anti-apoptotic gene, Bax is
the most important pro-apoptotic gene in this family,30
and the ratio between these two genes plays a role in
the physiological state. Previous experiments31 have
shown that Aβ can lead to increase toxicity in neural
stem cells, reduced Bcl-2 expression, increased Bax ex-
pression, and imbalanced Bax/Bcl-2 ratios, all of which
undermine the integrity of cell membranes.
Compared with the model group, Bcl-2 expression in-
creased and Bax, caspase-3, and Aβ expression de-
creased in the cortex of each QK treatment group. In
conclusion, QK significantly increased expression of
Bcl-2, down-regulated expression of Bax, caspase-3,
and Aβ, and reduced the number of apoptotic cells in
the cortex.
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Figure 2 Protein expression of Bcl-2, Bax, caspase-3, and Aβ in the cortex
A and E: protein levels of Bax in all groups. B and F: protein levels of Bcl-2 in all groups. C and G: protein levels of caspase-3 in all
groups. D and G: protein levels of Aβ in all groups. 0 + NS: normal control group (no treatment); NS + NS: sham-surgery group (no
treatment); Aβ + NS: model control group(no treatment); Aricept: treated with Aricept (1.67 mg·kg－1·d－1); L-FJ: treated with QK
(low dose of 4.75 mg·kg － 1·d － 1); M-FJ: treated with QK (medium dose of 9.5 mg·kg － 1·d － 1); H-FJ: treated with QK (high
dose of 19 mg·kg－1·d－1). NS: normal saline; Aβ: amyloid-β1-40 protein; L-FJ: low dose of QK (4.75 mg·kg－1·d－1); M-FJ: medium
dose of QK (9.5 mg·kg－1·d－1); H-FJ: high dose of QK (19 mg·kg－1·d－1). Data are presented as mean ± standard deviation (n = 6).
Significant differences compared with NS + NS (sham-surgery) group are designated as aP < 0.01 and with Aβ + NS (model con-
trol) group as bP < 0.01, cP < 0.01, and dP < 0.05.
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Figure 3 Immunohistochemical staining of the cortex (× 400)
A1-H1: OD level of BAX in all groups. A2-H2: OD level of Bcl-2 in all groups. A3-H3: OD level of caspase-3 in all groups. A4-H4: OD
level of Aβ in all groups. A: control; B: sham-surgery; C: control model; D: Aricept; E: low-dose QK; F: middle-dose QK; G: high-dose
QK. 0+NS: normal control group(no treatment); NS+NS: sham-surgery group (no treatment); Aβ+NS: model control group (no
treatment); Aricept: treated with Aricept (1.67 mg·kg－1·d－1); L-FJ: treated with QK (low dose of 4.75 mg·kg－1·d－1); M-FJ: treated
with QK (medium dose of 9.5 mg·kg－1·d－1); H-FJ: treatedwithQK (highdoseof 19mg·kg－1·d－1). NS: normal saline; Aβ: amyloid-β1-40protein; L-FJ: low dose of QK (4.75 mg·kg－1·d－1); M-FJ: medium dose of QK (9.5 mg·kg－1·d－1); H-FJ: high dose of QK (19 mg·kg－1·
d－ 1). Data are presented as mean ± standard deviation (n = 6). Significant differences compared with NS + NS (sham-surgery)
group are designated as aP < 0.01 and with Aβ + NS (model control) group as, bP < 0.01 and cP < 0.01.
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Figure 4 TUNEL staining showing cell apoptosis in the cortex (× 400)
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